Avelumab and Merkel Cell Carcinoma: Clinical Evidence Review on Causation

Legacy of General Health Communication

General health and science communication has long served as a foundation for public understanding of medical conditions and therapeutic options. In this tradition, audiences have been introduced to emerging treatments through accessible summaries that bridge clinical research and everyday health literacy. Within this legacy, the immune checkpoint inhibitor Avelumab has been presented as a therapeutic advance for Merkel cell carcinoma, a rare but aggressive skin cancer. Such general health narratives typically emphasize treatment efficacy and patient outcomes, framing the drug as a targeted intervention for those already diagnosed. Transitioning from this therapeutic perspective to an occupational exposure concern requires a shift in focus—from treatment to causation. In mass production environments, workers may encounter substances or conditions that could influence disease risk. While general health contexts highlight Avelumab as a treatment, the occupational lens asks whether exposure to certain agents—potentially including those related to Avelumab’s mechanism or manufacturing byproducts—could play a role in the development of Merkel cell carcinoma. This pivot does not assert causation but opens a line of inquiry: if a drug used to treat a cancer is itself linked to that cancer’s etiology under specific exposure conditions, then occupational health surveillance must consider such possibilities. Thus, the legacy of general health information provides a necessary baseline, while the occupational domain demands rigorous investigation into exposure pathways and risk factors, without prematurely invoking mechanistic claims.

Bridge from Treatment to Causation Inquiry

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). This agent is the first therapeutic specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is a rare but highly aggressive skin cancer with neuroendocrine differentiation, associated with chronic ultraviolet light exposure and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence of MCC is increasing, and it is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Clinical Evidence and Risk Context

The clinical presentation of MCC typically involves a rapidly growing, painless, firm, flesh-colored or red nodule on sun-exposed skin, often in older individuals. Diagnosis is confirmed by histopathology and immunohistochemistry, showing neuroendocrine markers such as cytokeratin 20 and chromogranin A. The disease is aggressive, with high rates of local recurrence, regional lymph node metastasis, and distant spread. Avelumab's mechanism of action involves blocking PD-L1, thereby preventing the inhibition of T-cell activity and enhancing the immune response against tumor cells. However, this immune activation can lead to immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). Reported adverse effects include hypercalcaemia secondary to reactivation of sarcoidosis, as described in a case of a patient with metastatic MCC on avelumab, which was managed with corticosteroids and allowed continuation of therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). Other immune-related adverse events are common with checkpoint inhibitors, though specific rates for avelumab in MCC are not detailed in the provided evidence. Mechanistic pathways linking avelumab to MCC are primarily therapeutic rather than causative. Avelumab is used to treat MCC, not to cause it. The evidence indicates that avelumab is an effective treatment for MCC, with response rates in chemotherapy-refractory patients (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, for patients who become refractory to avelumab, treatment options are limited. Studies have explored the use of ipilimumab plus nivolumab in avelumab-refractory MCC, showing that three out of five patients responded to this combination according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another multicenter study reported that immune checkpoint inhibition has improved outcomes, but response rates to PD-1/PD-L1 inhibition can be up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). A retrospective study noted that despite advances, about 50% of patients progress on immune checkpoint inhibitors, including avelumab (https://pubmed.ncbi.nlm.nih.gov/35877101/). Regarding risk considerations, the adequacy of warnings about avelumab and MCC is not directly addressed in the provided evidence. However, the evidence highlights that avelumab is approved for MCC treatment, and its use is associated with immune-related adverse events. For affected patients, causation considerations are relevant in the context of adverse events rather than MCC causation. The timeline between avelumab exposure and documented harm, such as immune-related adverse events, can vary. In the case of hypercalcaemia due to sarcoidosis reactivation, the event occurred during treatment with avelumab, and resolution was achieved with corticosteroids while continuing avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). For avelumab-refractory disease, the timeline of progression is not specified in the evidence, but it is noted that approximately half of patients progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). In summary, avelumab is a PD-L1 inhibitor approved for metastatic MCC, with demonstrated efficacy in a subset of patients. Its use is associated with immune-related adverse events, which can be managed. The evidence does not support a causal link between avelumab and the development of MCC; rather, avelumab is a treatment for the disease. For patients who are refractory to avelumab, alternative immunotherapies such as ipilimumab plus nivolumab may offer benefit. The risk narrative should emphasize that avelumab is a therapeutic agent for MCC, and adverse events are related to its immune-modulating effects, not to causation of the cancer itself.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can avelumab cause Merkel cell carcinoma?

No, the evidence does not support a causal link between avelumab and the development of Merkel cell carcinoma. Avelumab is a treatment for MCC, not a cause. It is a PD-L1 inhibitor approved for metastatic MCC and works by enhancing the immune response against tumor cells.

What are the common adverse events associated with avelumab?

Avelumab can cause immune-related adverse events due to overactivation of the immune system. Reported events include hypercalcaemia secondary to reactivation of sarcoidosis, which can be managed with corticosteroids. Other irAEs are common with checkpoint inhibitors but specific rates for avelumab in MCC are not detailed in the provided evidence.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.